Biotech RadarJobs updated

COMPANY

Alumis

HQ: South San Francisco, CA source · alumis.com ↗ · West Coast

Clinical Phase 3

6 open jobs · last seen Oct 23, 2026 · 16 sources

Keywords: immunology Plaque Psoriasis SLE Hepatic Impairment Psoriasis Moderate Psoriasis Severe Psoriasis Renal Impairment Uveitis Posterior Non-Infectious Intermediate Uveitis Noninfectious Panuveitis Safety and Tolerability envudeucitinib ESK-001 A-005

Location: South San Francisco, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Since the raise (Jan 9, 2026): 6 of 6 open jobs were first seen after it.

6Open jobs$345.1MRaised (2 yrs)13Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Medical Science LiaisonUnited StatesSep 22, 2026Oct 9, 2026
Director, Medical AffairsSouth San Francisco Aug 31, 2026Oct 9, 2026
Medical Outcomes LiaisonUnited StatesJun 17, 2026Oct 9, 2026
Senior Director, Medical Strategy and OperationsUnited StatesApr 30, 2026Oct 9, 2026
Senior/Executive Medical Director, Clinical Development (New Indications)South San FranciscoApr 10, 2026Oct 9, 2026

See all 6 jobs

Timeline

  1. Board tracked Radar started tracking this company’s job board (6 open jobs at last check). source ↗
  2. Raise Follow-on offering: $345.1M (total, as published), announced Jan 9, 2026. Source: company release on GlobeNewswire. source ↗
  3. Trial start Phase 1: An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage source ↗
  4. Trial start Phase 1: An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function source ↗
  5. Partnership Partnership / licensing: $40M (upfront, as published), announced Mar 25, 2025. Source: SEC filing. source ↗
  6. Trial start Phase 3: Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis source ↗
  7. Trial start Phase 3: A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 source ↗
  8. Trial start Phase 3: A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis source ↗
  9. Trial start Phase 1: An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001 source ↗
  10. Trial start Phase 1: An Investigational Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of A-005 source ↗
  11. Trial start 2: Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus source ↗
  12. Trial start Phase 2: POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIU source ↗
  13. Trial start Phase 2: Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis source ↗
  14. Trial start Phase 2: A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis source ↗
  15. Trial start Phase 1: Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy Participants source ↗
  16. Trial start Phase 1: Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 6

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Medical Science LiaisonUnited StatesSep 22, 2026Oct 9, 2026Mid
Director, Medical AffairsSouth San Francisco Aug 31, 2026Oct 9, 2026Senior
Medical Outcomes LiaisonUnited StatesJun 17, 2026Oct 9, 2026Mid
Senior Director, Medical Strategy and OperationsUnited StatesApr 30, 2026Oct 9, 2026Senior
Senior/Executive Medical Director, Clinical Development (New Indications)South San FranciscoApr 10, 2026Oct 9, 2026Executive
Vice President, Medical AffairsSouth San FranciscoJan 26, 2026Oct 9, 2026Executive

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Funding

Raised: $345.1M. Last 2 years.

Clinical trials (lead sponsor) 13

RecordTitlePhaseStatusStartPrimary completion
NCT06588738A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001Phase 3CompletedAug 20, 2024Sep 23, 2025 (actual)
NCT06586112A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque PsoriasisPhase 3CompletedJul 25, 2024Sep 19, 2025 (actual)
NCT05739435Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque PsoriasisPhase 2Active, not recruitingJan 17, 2023Dec 1, 2027 (estimated)
NCT05966480Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus2Active, not recruitingJun 26, 2023Jun 23, 2026 (actual)
NCT06952634An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver DamagePhase 1CompletedApr 29, 2025Mar 24, 2026 (actual)
NCT06846541Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque PsoriasisPhase 3Active, not recruitingJan 8, 20252028-11 (estimated)
NCT07442149An Investigational Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of A-005Phase 1CompletedApr 22, 2024Dec 18, 2024 (actual)
NCT07378579An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001Phase 1CompletedJun 21, 2024Aug 31, 2024 (actual)
NCT06962774An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal FunctionPhase 1CompletedApr 23, 2025Aug 1, 2025 (actual)
NCT05600036A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque PsoriasisPhase 2CompletedSep 27, 2022Jun 29, 2023 (actual)
NCT05953688POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIUPhase 2TerminatedJun 14, 2023Aug 13, 2024 (actual)
NCT05431634Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy ParticipantsPhase 1CompletedMay 12, 2022Dec 1, 2022 (actual)
NCT05330858Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy ParticipantsPhase 1CompletedMar 17, 2022Jun 30, 2022 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Connect

See your connections at Alumis on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Feedback